Filing Signals

Source: SEC EDGAR Compiled 2026-08-23 04:41 UTC Unattended

← All events

DNA X, Inc.

CIK 1178697 SONM·Manufacturing · All EDGAR filings ↗

Late filing elevated Filing comparison

DNA X, Inc. filed its quarterly report late and said it expects a significant change in results

expects significant change in results

(the “Company”) is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the three months ended June 30, 2026 (the “Form 10-Q”) within the prescribed time period. This delay resulted primarily from accounting for the sale of convertible debt during the period and from the complexities associated with accounting for variable interest entities under Accounting Standards Codification (“ASC”) Topic 810, Consolidation. As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 27, 2026 (the “Termination Date”), the Company entered into an Amendment No. 1 to Membership Interest Purchase Agreement with DNA
Evidence
Anticipates significant change
True
Other periodic reports filed
None
Severity
high
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”) is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the three months ended June 30, 2026 (the “Form 10-Q”) within the prescribed time period. This delay resulted primarily from accounting for the sale of convertible debt during the period and from the complexities associated with accounting for variable interest entities under Accounting Standards Codification (“ASC”) Topic 810, Consolidation. As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 27, 2026 (the “Termination Date”), the Company entered into an Amendment No. 1 to Membership Interest Purchase Agreement with DNA
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.